Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.68 |
| ▸ | NPY1R | P25929 | 11/20 | 0.68 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.68 |
| ▸ | NPY2R | P49146 | 7/20 | 0.68 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.60 |
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12794641 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL17356289 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL13563457 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL18951648 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL19278452 | 0.97 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL12792696 | 0.96 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13563464 | 0.96 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| Trifluoroacetic Acid SCHEMBL22126685 | 0.95 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL16507923 | 0.95 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL13563435 | 0.95 | KISS1R (0.62) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224251-A1 | METHODS OF DIFFERENTIATING STEM CELLS INTO ENDODERM | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-07-25 | — | — | US | disclosed |
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9518083-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | IP2IPO INNOVATIONS LIMITED (GB) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | NPY4R 4859/4885NPY1R 4857/4885NPY5R 4808/4885 |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | NPY4R 2105/4885NPY1R 3277/4885NPY5R 2756/4885 |
| US-20190224251-A1 | METHODS OF DIFFERENTIATING STEM CELLS INTO ENDODERM | ALPG, ALPP, ALPI | NPY4R 4309/4885NPY1R 4055/4885NPY5R 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.